Histogen (Histogen) Interest Expense : $0.00 Mil (TTM As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Histogen Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Histogen's interest expense for the three months ended in Sep. 2023 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Histogen's Operating Income for the three months ended in Sep. 2023 was $ -3.53 Mil. Histogen's Interest Expense for the three months ended in Sep. 2023 was $ 0.00 Mil. Histogen has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Histogen Interest Expense Historical Data

The historical data trend for Histogen's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Histogen Interest Expense Chart

Histogen Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Interest Expense

-0.06

-0.01

Histogen Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Interest Expense	Get a 7-Day Free Trial													-	-	-	-	-

Histogen Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Histogen (OTCPK:HSTO) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Histogen's Interest Expense for the three months ended in Sep. 2023 was $0.00 Mil. Its Operating Income for the three months ended in Sep. 2023 was $-3.53 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2023 was $0.00 Mil.

Histogen's Interest Coverage for the quarter that ended in Sep. 2023 is calculated as

Histogen had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Histogen (Histogen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Histogen Inc (OTCPK:HSTO) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

10655 Sorrento Valley Road, Suite 200, San Diego, CA, USA, 92121

Website

https://www.histogen.com

Histogen Inc is a clinical-stage therapeutics company focused on developing proprietary hypoxia-generated growth factor technology platforms and stem cell-free biologic products as potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function. Under its biologics technology platform, the product candidates in development are HST-003, a treatment for joint cartilage repair, and HST-004, a treatment for spinal disc repair. It also has a pipeline of clinical and preclinical small molecule pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases that the company intends to develop.

Executives

Joyce Reyes	officer: See Remarks	10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Richard W Pascoe	director, officer: See Remarks	C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Rochelle Fuhrmann	director	C/O WARNER CHILCOTT CORPORATION, 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866
Susan Richards Windham-bannister	director	78 BLANCHARD ROAD, BURLINGTON MA 01803
Moya Daniels	officer: See Remarks	10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Susan A. Knudson	officer: See Remarks	9191 TOWNE CENTRE DRIVE, SUITE 400, SAN DIEGO CA 92121
Jonathan Jackson	director, 10 percent owner	C/O HISTOGEN INC., 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Gail K Naughton	officer: See Remarks	C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
David Hugh Crean	director	C/O HISTOGEN INC., 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Stephen Chang	director	12912 CAMINO DEL VALLE, POWAY CA 92064
Brian Satz	director	C/O HISTOGEN INC., 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Yizhuo Zhang	director	C/O HISTOGEN INC., 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Martin Latterich	officer: See Remarks	C/O HISTOGEN INC., 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Steven J Mento	director	C/O SANGAMO BIOSCIENCES, INC., 501 CANAL BLVD SUITE A-100, RICHMOND CA 94804
Keith W Marshall	officer: EVP, COO & CFO	C/O CONATUS PHARMACEUTICALS INC., 16745 WEST BERNARDO DRIVE, SUITE 200, SAN DIEGO CA 92127